B+
Bull case
25%
Probability
Target price
$171.17
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
ATR
AptarGroupBNYSE / Materials
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$150.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$120.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
+24.3
Positive
Company
-
Unavailable
Macro
+24.3
Positive
Pulse
-
Unavailable
Weekly research (10D)
-24.0
Negative
Sentiment proxy
+86.6
Score
AI commentary
The company’s Q2 release provides concrete confirmation of the EPS beat and Q3 guidance, but no verified post-print share-price reaction or analyst revision signal is available in the packet. Missing market and analyst reaction is not treated as positive evidence, so this remains a cautious monitoring view. [#SEC-8K-2026-07-30]
RankAlpha Sentiment Codex - 2026-08-04
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-07-30eventQ2 earnings beat with explicit Q3 guidanceMedium impact
Aptar's Q2 company release reported sales up 6% to $1.03 billion, adjusted EPS of $1.42 and adjusted EBITDA margin of 20.7% versus 22.6% a year earlier. Management guided Q3 2026 adjusted EPS to $1.45-$1.53 and described expected growth across all three segments. [#SEC-8K-2026-07-30]
2026-09-01eventCEO successionMedium impact
Gael Touya is scheduled to assume the CEO role on September 1, 2026. The transition appears planned, but execution and capital-allocation continuity remain watch items. [#EARNINGS-TRANSCRIPT-2026Q2] [#SEC-8K-2026-07-30]
2026-11-02catalystEmergency-medicine destocking remains a near-term headwindMedium impact
The company expects emergency-medicine destocking to abate by Q4, while Q3 Pharma demand excluding emergency medicine remains strong. Beauty and Closures still face product-mix and operational execution pressure. [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology